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Background: Cystic fibrosis (CF) affects the lungs causing infections and inflammation. Surfactant protein D (SP-D) is an innate defense lectin
primarily secreted in the lungs. We investigated the influence of the SP-D Met11Thr polymorphism on CF lung function; and serum SP-D as a
marker for CF lung disease.
Methods: For 107 CF patients (73 children, and 34 adults) serum SP-D and SP-D Met11Thr genotype were available. Leukocyte count was
obtained for a subset of patients. Lung function was measured as forced expiratory volume in one second (FEV-1).
Results: Serum SP-D was increased in CF patients compared to healthy controls, positively correlated to leukocyte count, and negatively
correlated to FEV-1. We found no correlation between SP-D Met11Thr genotype and FEV-1, and we found corresponding genotype frequencies
in CF patients and in healthy controls.
Conclusion: Serum SP-D in CF patients was increased in parallel with leukocyte count and with reduced FEV-1 and may constitute an alternative
biomarker for lung disease, in the clinical setting and in research.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.1. Background
Surfactant protein D (SP-D) is a lectin primarily secreted by
alveolar type II cells in the lungs. SP-D forms part of the innate
immune system. It binds carbohydrates, and in special cases
lipids and free fatty acids on pathogen surfaces; promotes the
phagocytosis of the two most prominent bacteria infecting the
cystic fibrosis lung, Staphylococcus aureus and Pseudomonas
aeruginosa [1,2], and enhances the release of tumor necrosis
factor α in response to lipopolysaccharide [2]. Lately, SP-D has
also been proposed as a target for free oxygen radicals, altering
its structure and thereby inhibiting its function [3].
Cystic fibrosis is caused by an autosomal recessive inherited
defect in the ion channel protein, cystic fibrosis membrane
regulator (CFTR). The main result of this is a state of chronic
inflammation in the lung, accentuated by recurrent and eventually
chronic infections. Furthermore, there seems to be a state of⁎ Corresponding author. Pediatric Department A Aarhus University Hospital
Skejby 8200 Aarhus N, Denmark. Tel.: +45 89 49 67 40; fax: + 45 89 49 60 23.
E-mail address: hvo@dadlnet.dk (H.V. Olesen).
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.03.011excessive oxidative stress in the CF lung [4,5], maybe caused by
failure ofCFTR to transport the oxygen scavenger glutathione [6].
Hence, surfactant protein D has a potential role in cystic
fibrosis (CF) lung disease. This role is double, since SP-D forms
part of the innate immune system primarily in the lungs, and lung
infections are the main life-threatening feature of CF in patients.
Secondly, excessive oxidative stress in the CF lungs could be
influenced by the ability of SP-D to work as an oxygen scavenger
and thereby alleviate the inherent harmful defect in CF patients.
Therefore, any changes in SP-D secretion or degradation may
potentially influence the course of CF lung disease.
In other patients with acute or chronic lung injury, circulating
SP-D has been found in high levels, and serum SP-D has been
suggested as a biomarker in multiple inflammatory pulmonary
diseases [7–11]. So far, serum SP-D has been investigated in a
small, short term study on 11 CF patients [12]. These patients
had higher serum SP-D than controls, and values suggested an
inverse relationship between serum SP-D and lung function.
We studied the correlation between serum SP-D and various
factors as age, leukocyte count and lung function in a larger
group of patients with cystic fibrosis.d by Elsevier B.V. All rights reserved.
258 H.V. Olesen et al. / Journal of Cystic Fibrosis 9 (2010) 257–262Secretion of SP-D and the resulting serum levels are not
governed by inflammation and infection alone, also genetic
factors play a role. Several polymorphisms of the SP-D gene
have been described [13,14]. The most thoroughly investigated
polymorphism is the Met11Thr variation, a substitution of
threonine for methionine at amino acid position 11 in the mature
protein. The Thr/Thr 11 individuals have lower levels of serum
SP-D than those with Met/Met 11 [13], and the polymorphism
accounts for approximately 50% of the genetic variation in
serum levels in twin studies [15]. The Thr/Thr 11 variant causes a
reduction in the formation ofmultimers of SP-D, thereby reducing
its avidity towards the target.
Even if no known disease entity has been described to
originate solely from this polymorphism of SP-D, CF patients
with incessant pulmonary inflammation and infection may be
affected by changes in the SP-D homeostasis. Because of this
continuous stress, evenminor changes in the pulmonary immune
system may be pivotal for the patients' ability to cope with the
unavoidable infections.
In this cross-sectional study, we investigated the influence of
the SP-D Met11Thr polymorphism on CF lung function.
2. Methods
2.1. Study subjects
2.1.1. Patients
All participating patients attended the CF Centre, Aarhus
University Hospital Skejby during the study period. Patients
were genotyped for the SP-D single-nucleotide polymorphism
Met11thr, and had serum SP-D measured at one occasion.
For 107 patients (73 children, and 34 adults) both serum SP-D
and SP-D Met11Thr allelic variations were available. In total,
118 patients (82 children, and 36 adults) were genotyped and
111 (76 children, and 35 adults) patients had serum SP-D
measured. Ninety seven patients of the 107 (and 107 of the 118
with SP-D genotype) were homozygous or compound hetero-
zygous for class I, II or III CF mutations (severe CF mutations).
These mutations all result in absence of or non-functional cysticTable 1
Demographic data of 111 patients with serum SP-D measurement.
Age (yrs) a Male:female
All CF patients
(76 children, and 35 adults)
13 (8; 22) 60:51
Severe CF mutationsd
(n=101)
12 (7; 19) 57:44
Severe CF mutations d
Adults (n=27)
25 (23; 31) 7:20
Severe CF mutations d
Childrenb19 years (n=74)
10 (6; 13) 37:37
a Age at date of serum sampling and FEV-1 presented as median (25th; 75th perc
b Patients homozygous for the CF-mutation delta F508.
c n = number of patients with FEV-1 value available at day of serum sampling.
d Homozygous or compound heterozygous for classes I, II or III CF mutations (seve
regulator (CFTR)).fibrosis transmembrane regulator (CFTR). Of these patients,
78% were homozygous for the most common CFTR mutation,
delta F 508 (class II). Demographics and key clinical parameters
of the 111 patients with serum SP-D values are summarized in
Table 1.
Adult patients were defined as ≥18 years at the time of
blood sampling.
The study was approved by the Ethics Committee of Aarhus
County (file no 20010100) and patients were recruited after in-
formed consent. All demographic and clinical data were extracted
from the Danish CF Registry.
2.1.2. SP-D reference population
288 healthy non-smokingDanish twin individuals, 18–67 years
old, matched for age and gender served as control population [15].
Non-smoking adults were selected because none of the CF patients
were smokers. One random individual of each twin pair was
deleted before analysis of genotype frequencies. For children the
serum SP-D reference values were obtained from a population of
128 (64 twin pairs) 6–9 year-old children [16].These two reference
populations were selected for preliminary studies of SP-D
concentration and genotype.
2.2. Study design
The study was performed as a cross-sectional study with
follow-up on lung function testing after two to three years. At
inclusion, serum SP-D, leukocyte count and forced expiratory
volume in the first second (FEV-1) were registered. Maximum
FEV-1 values for the year of study start were extracted from the
Danish CF Registry. SP-D genotype was analyzed for the
patients included at study start, but also for patients attending
the centre later during the study period.
2.2.1. Serum SP-D concentration
Blood samples were drawn at a routine visit at the outpatient
clinic. SP-D was quantified in serum by a five-layered ELISA,
as previously described [8]. Microtitre plates were coated with
F(ab′)2 anti-human SP-D IgG (K477) at 1 µg/ml in 0.05 MDelta F 508 homozygotes b FEV-1a
(% of predicted)
80 (72%) 69.9 (42.0;84.5) (n=88) c
80 (79%) 71.4 (45.7;85.7) (n=78) c
21 (78%) 46.0 (31.0;64.4) (n=24) c
59 (78%) 76.3 (57.2;88.0) (n=54) c
entile).
re CF mutations with absence of or non-functional cystic fibrosis transmembrane
Table 2
Serum SP-D in CF patients and healthy controls.
N Serum SP-D; ng/mL
Median (25; 75 percentile)
Fold
increase
p-value
Adult controls (Ref. [15]) 288 779 (615; 1119) –
All adult CF patients 35 1660 (1252; 2216) 2.1 b0.001
Severe CF mutations
adults
27 1820 (1120; 2169) 2.4 0.001
Control children aged 6 to
9 (Ref. [16])
64 658 (478; 899) –
All CF children 76 1442 (880; 2063) 2.2 b0.001
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4 °C, the plates were washed and left with washing buffer
(TBS, 0.05% (w/v) Tween 20, 5 mM CaCl2) for 15 min at room
temperature as a blocking step. Calibrator, control samples, and
samples diluted as appropriate (×500–4000) were then added and
incubated over night at 4 °C. This was followed by successive
incubations with biotinylated monoclonal anti-human SP-D
antibody (Hyb 246-4), horseradish peroxidase-conjugated strep-
tavidin and o-phenylenediamine in citrate–phosphate buffer, pH
5, containing 0.014% H2O2. H2SO4 stopped the color reaction.
Plates were read at 492 nm in a multi-channel spectrophotometer.
All assayswere performed in duplicate. Thismethod detects SP-D
both as intact trimers and multimers, as well as fragmented SP-D
with intact carbohydrate recognition domain.
2.2.2. SP-D genotypes
Genomic DNA was extracted from 200 μl of frozen anti-
coagulated blood using the QIAamp DNA blood mini kit (Qiagen,
Hilden, Germany) according to the manufacturer's instructions.
Primers and probes for the non-synonymous SNP CT
substitution in position 92 in the SFTPD exon 1 resulting in the
Met11Thr variant were designed by the manufacturer (Applied
Biosystems, Assay-by-design).
In the assay, the reaction was carried out in a final volume of
5 μl (to a final concentration of 900 nM primers and 200 nM
probe, respectively) added to dry DNA (15–50 ng) in optical
384-well plates sealed with optical covers. The primer/probe
combination was designed to work at one universal set of thermal
cycler conditions: 50 °C for 2 min, 95°C for 10 min, followed by
40 cycles at 95°C for 15 s and 60°C for 60 s. The thermal cyclers
used for this reaction were GeneAmp PCR System 9700 (Applied
Biosystems) with 384-well thermal blocks. After thermal cycling,
the plates were stored at 4°C (never more than 48 h) until they
could be read by the fluorescent reader.
Fluorescent signals were detected in an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems). Results were
collected and analyzed by ABI PRISM SDS 2.1 software for
allelic discrimination.
2.2.3. Leucocyte count
Blood leukocyte count was registered for a subset of 76 of
the patients at the day of serum SP-D measurement. Because of
the wide age span of the patients (0 to 74 years), and hence the
span of normal upper range of leukocyte count, we correlated
the leukocyte count to normal age references using Soldin [17]
for children and Nordin for adults [18], calculating a leukocyte
index (leukocyte count/highest normal reference).
2.2.4. Lung function
Standard spirometry was performed using a Pneumotach
Spirometer (Jaeger, Germany) at every visit with measurements
of FEV-1. These were obtained in patients from approximately
six years of age. Reference values for calculation of FEV-1% of
predicted (FEV-1%) for children were obtained from Solymar
[19] and for adults Quanjer [20]. The FEV-1% on sampling date
was recorded (FEV-1sample). The highest FEV-1% for the year
of sampling was recorded as a baseline value (FEV-1max).2.2.5. Statistical analyses
Analyses were either corrected for cystic fibrosis genotype
(severe/non-severe), or performed for both all and severe geno-
types only. No difference in significance was seen between the
two groups. Where nothing else is mentioned the values for
patients with severe CF mutations is given.
The serum SP-D levels from the adult CF patients were
compared with the mean SP-D levels generated from healthy
controls matched to the patients according to age (in years) and
gender. The mean control SP-D values were calculated from
2 to 25 individuals (all available individuals after matching).
The equality of matched pairs was tested by the sign test. For
children we used the Mann–Whitney test: A random child of
each twin pair was selected for analysis and these values were
compared to those of the CF children. This method was used in
preference to the method used for adults because of the lower
number of controls.
We used Kruskal–Wallis for comparison of SP-D genotype
and SP-D concentration. Distribution of SP-D genotypes in CF
patients compared to the population was analyzed using Chi-
square test.
Pearson correlation analysis was performed for serum SP-D
and age, corrected for FEV-1%.
Pearson correlation analysis was calculated for serum SP-D
and FEV-1%, with correction for age. Multiple linear regression
analysis was performed for FEV-1% and SP-D with SP-D Met/
Thr 11 genotype as independent dummy variable, correcting for
age and CF genotype.
Multiple linear regression analysiswas performed for FEV-1%
and with SP-D Met/Thr 11 genotype as independent variable,
correcting for age and CF genotype.
All results were considered statistically significant at the 0.05
level. Analyses were performed using SPSS 15.0 and 17.0.
3. Results
3.1. Serum SP-D in CF and healthy controls
Both CF children and adults had significantly increased SP-D
values compared to corresponding controls (Table 2). Indeed,
71% of CF children and 77% of CF adults had serum SP-D values
higher than the 75 percentile for the reference populations. Adult
CF patients did not have significantly higher serum SP-D than CF
children (p=0.18).
Fig. 1. Correlation coefficients of serum SP-D and FEV-1% for patients with
severe CF mutations. Diamonds shows correlations coefficients (◊=adults,
♦=children). Whiskers represent 95% CI of the correlation coefficient. aThe
correlation analyses were performed with correction for age at sampling.
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for all patients (r=0.107; p=0.27), nor for the subgroup with
severe CF mutations (r=0.148; p=0.14).
3.2. SP-D Met11Thr SNP distribution and serum SP-D
SP-D Met11Thr variants were distributed similarly in CF
patients and in the reference population (Table 3).
There was no significant difference in serum SP-D for the
three Met11Thr variants (MM, MT and TT), except in children
where the TT patients showed significantly lower serum SP-D
than the MM patients, as described previously (Table 3) [13,15].
3.3. Serum SP-D and leukocyte count
Blood leukocyte count measured on the day of serum SP-D
blood sampling was used as a marker of inflammation. The
SP-D concentration was significantly higher in the fraction of
patients with a leukocyte count above normal reference (n=36;
median1822 (25; 75 percentiles 1224; 2399) ng/mL) than in
the fraction with normal leukocyte count (n=40; 1372 (804; 1827)
ng/mL; p=0.013). Furthermore, we found a significant correlation
between serum SP-D and leukocyte index (r=0.26, p=0.026).
3.4. Serum SP-D and lung function
We correlated serum SP-D to both FEV-1% at day of
sampling, as well as the maximum FEV-1% of the study year,
correcting for age. Both FEV-1% values correlated negatively
and significantly to serum SP-D (ρ=−0.399; p=0.001 and ρ=
−0.437; pb0.001 respectively). This was true as well for adults
and children separately (Fig. 1).
Since serum SP-D was in some degree dependent on SP-D
genotype we also performed regression analysis of serum SP-D
and FEV-1% corrected for SP-D genotype. Serum SP-D and
FEV-1%max was significantly interdependent with B=−0.010
(pb0.001). Age added significantly to the model (pb0.001),
but the relationship between serum SP-D and FEV-1%
remained approximately the same (B=−0.0097, pb0.001)
after age correction. SP-D genotype did not influence the result
(p=0.42 for MM genotype, p=0.32 for MT genotype compared
to TT), neither did CF genotype (p=0.46 for severe vs non-
severe) Similar figures were found when using FEV-1%sample.Table 3
SP-D genotypes (Met11Thr) for all patients with genotyping performed and serum
Number of patients Met/Met 11
Reference population (n=143)
Median serum SP-D ng/ml (25; 75%)
46 (32.2%)
800 (608; 1214)
All CF patients (n=118)
Median serum SP-D ng/ml (25; 75%)
40 (33.9%)
1603 (981; 2380)
Severe CF mutations adults (n=40)
Median serum SP-D ng/ml (25; 75%)
11 (27.5%)
1646 (985; 2192)
Severe CF mutations children (n=67)
Median serum SP-D ng/ml (25; 75%)
25 (37.3%)
1535 (904; 2523)
a Significant difference in serum SP-D concentration between Met/Met 11 and Th3.5. SP-D Met11Thr SNP distribution and lung function
FEV-1%max was not correlated to SP-D Met11thr genotype
(Fig. 2). Multiple linear regression of FEV-1% and the SP-D
genotype showed no significant interdependence (MM and MT
genotypes were not significantly different from TT genotypes;
p=0.57 and p=0.54, respectively). Correction for age and CF
genotype added nothing to the model.
4. Conclusions
Serum SP-D is significantly higher in patients with cystic
fibrosis than in age-matched healthy controls, with 1.5 to 3-fold
higher median values, and it correlates negatively with FEV-1.
We have hereby confirmed the findings of Krane et al. [12] in a
much larger, unselected CF population covering all age groups.
The increased serum levels imply a high SP-D production in the
CF lungs, possible leakage from injured airways and further
inductionwith increased inflammation and infection. This contrasts
the very low values of SP-D found in CF broncho-alveolar lavage
fluid (BALF) [3,21,22]. The high serum values support the theory
that the relative lack of SP-D in BALF is due to increased
degradation and circulatory leakage rather than impaired produc-
tion [3,12]. Degradation may be further enhanced by the
considerable oxidative stress in the CF lungs [4,5]. The oxidativeSP-D concentration for patients with both parameters reported.
Met/Thr 11 Thr/Thr 11
67 (46.8%)
785 (609; 1111)
30 (21.0%)
747 (542; 1042)
55 (46.6%)
1520 (1109; 2026)
23 (19.5%)
1193 (673; 2146)
19 (47.5%)
2054 (1148; 2527)
10 (25.0%)
1660 (1119; 2134)
30 (44.8%)
1501 (929; 1979)
12 (17.9%)
933 (565; 1748) a
r/Thr 11 patients, p=0.032.
Fig. 2. FEV-1 for different SP-D Met11Thr genotypes. a) CF children, b) CF
adults. Solid line represents median, box represents 25 and 75 percentiles, * are
outliers.
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However, recent research has discovered a decreased amount of the
free oxygen radical scavenger, glutathione, in the CF lung. Indeed,
this is not only because of excessive consumption but because this
small anion is normally transported by the CFTR chloride channel
which is malfunctioning in CF patients [6]. This exerts pressure on
other oxygen scavengers. Since SP-D appears to be an oxygen
radical scavenger with altered effect after oxidation this furthers its
malfunction in CF lungs [3].
The reported association between SP-D Met11Thr variation
and serum SP-D in healthy adults could not be confirmed for the
complete patient population [13,15]. Lower serum concentra-
tions in Thr/Thr11 individuals were present in the children, but
were apparently obscured in the adult CF patients (Table 3).
This probably results from a high degree of induction in older
patients, with increasing lung damage and inflammation
blurring the genotype effect on the serum levels.
There was no apparent association between SP-D Met11Thr
variation and lung function, nor was there any difference in SP-D
genotype distribution between CF patients and healthy blood
donors (Table 3). However, we observed an insignificant shift
towards more Thr/Thr11 patients in the adult than in the child CF
population. Our number of adult patients is low and investiga-
tion in larger patient groups will be required to elucidate further
the role of genetic SP-D variation in CF.
Additionally, we observed a significant negative correlation
between serum SP-D and lung function, represented by FEV-1.
The CF lung disease represents a chronic state of inflammation,
augmented by recurrent and eventually often chronic infection.
The lung function is a consequence of this with a gradual decline
and more acute fluctuations. Consequently, serum SP-D may
reflect both acute and chronic lung damage and thereby both
acute and chronic variations in lung function. We correlated
serum SP-D with lung function, both at the day of blood
sampling and as the maximum value of that year, and found a
significant negative correlation at all times.
We saw a positive correlation between leukocyte count and
serumSP-D in a subset of our patients, indicating that serumSP-Dmay be just an alternative to leukocyte count as an inflammatory
marker. However, in acute pneumonia, leukocyte count is shown
to return to normal within a few days, whereas serum SP-D
remains higher than controls at least 21 days after admission to
hospital [8]. In cystic fibrosis leukocyte count (and C-reactive
protein levels) are significantly reduced following a course of
intravenous antibiotics [23], and the only longitudinal study of
serum SP-D in CF is the small study by Krane et al. [12] who
showed no change in SP-D serum levels over 32 weeks in 11
patients with allergic broncho-pulmonary aspergillosis going
through a course of oral steroids and intraconazole. Similar find-
ings have been reported in Chronic Obstructive Pulmonary
Disease (COPD) where serum SP-D, but not serum-C-reactive
protein, was correlated to FEV-1 and chronic respiratory disease
questionnaire scores [10]. Thus, there is evidence that serum SP-D
may be a more stabile marker of inflammation than blood leu-
kocyte count. A longer prospective study including variations
in serum SP-D over time and correlation to treatment of lung
inflammation and/or infection is necessary to substantiate these
preliminary findings. The fact that serum SP-D seems to be steroid
dependent in COPD [11], and the reports on SP-D acting as an
oxygen radical scavenger [3] also makes serum SP-D a possible
surrogate endpoint measure in clinical trials of anti-inflammatory
and gene modulating drugs in CF.
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